173 related articles for article (PubMed ID: 33703881)
1.
Lenka S; Singh D; Paul S; Gayen A; Chandra M
ACS Infect Dis; 2021 Apr; 7(4):733-745. PubMed ID: 33703881
[TBL] [Abstract][Full Text] [Related]
2. Comparative study of Bifidobacterium animalis, Escherichia coli, Lactobacillus casei and Saccharomyces boulardii probiotic properties.
Martins FS; Silva AA; Vieira AT; Barbosa FH; Arantes RM; Teixeira MM; Nicoli JR
Arch Microbiol; 2009 Aug; 191(8):623-30. PubMed ID: 19526225
[TBL] [Abstract][Full Text] [Related]
3. Adhesion to the yeast cell surface as a mechanism for trapping pathogenic bacteria by Saccharomyces probiotics.
Tiago FCP; Martins FS; Souza ELS; Pimenta PFP; Araujo HRC; Castro IM; Brandão RL; Nicoli JR
J Med Microbiol; 2012 Sep; 61(Pt 9):1194-1207. PubMed ID: 22580913
[TBL] [Abstract][Full Text] [Related]
4. Enhancing probiotic impact: engineering
de Carvalho BT; Subotić A; Vandecruys P; Deleu S; Vermeire S; Thevelein JM
Appl Environ Microbiol; 2024 Jun; 90(6):e0032524. PubMed ID: 38752748
[No Abstract] [Full Text] [Related]
5. Unique genetic basis of the distinct antibiotic potency of high acetic acid production in the probiotic yeast
Offei B; Vandecruys P; De Graeve S; Foulquié-Moreno MR; Thevelein JM
Genome Res; 2019 Sep; 29(9):1478-1494. PubMed ID: 31467028
[TBL] [Abstract][Full Text] [Related]
6. Novel insights in genetic transformation of the probiotic yeast Saccharomyces boulardii.
Douradinha B; Reis VC; Rogers MB; Torres FA; Evans JD; Marques ET
Bioengineered; 2014; 5(1):21-9. PubMed ID: 24013355
[TBL] [Abstract][Full Text] [Related]
7. Yeasts as probiotics: Mechanisms, outcomes, and future potential.
Sen S; Mansell TJ
Fungal Genet Biol; 2020 Apr; 137():103333. PubMed ID: 31923554
[TBL] [Abstract][Full Text] [Related]
8. Review article: yeast as probiotics -- Saccharomyces boulardii.
Czerucka D; Piche T; Rampal P
Aliment Pharmacol Ther; 2007 Sep; 26(6):767-78. PubMed ID: 17767461
[TBL] [Abstract][Full Text] [Related]
9. Saccharomyces boulardii administration changes gut microbiota and reduces hepatic steatosis, low-grade inflammation, and fat mass in obese and type 2 diabetic db/db mice.
Everard A; Matamoros S; Geurts L; Delzenne NM; Cani PD
mBio; 2014 Jun; 5(3):e01011-14. PubMed ID: 24917595
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the Probiotic Yeast Saccharomyces boulardii in the Healthy Mucosal Immune System.
Hudson LE; McDermott CD; Stewart TP; Hudson WH; Rios D; Fasken MB; Corbett AH; Lamb TJ
PLoS One; 2016; 11(4):e0153351. PubMed ID: 27064405
[TBL] [Abstract][Full Text] [Related]
11. Production of neoagarooligosaccharides by probiotic yeast Saccharomyces cerevisiae var. boulardii engineered as a microbial cell factory.
Jin Y; Yu S; Liu JJ; Yun EJ; Lee JW; Jin YS; Kim KH
Microb Cell Fact; 2021 Aug; 20(1):160. PubMed ID: 34407819
[TBL] [Abstract][Full Text] [Related]
12. Quality control of fifteen probiotic products containing Saccharomyces boulardii.
Vanhee LM; Goemé F; Nelis HJ; Coenye T
J Appl Microbiol; 2010 Nov; 109(5):1745-52. PubMed ID: 20636342
[TBL] [Abstract][Full Text] [Related]
13. Influence of oral intake of Saccharomyces boulardii on Escherichia coli in enteric flora.
Akil I; Yilmaz O; Kurutepe S; Degerli K; Kavukcu S
Pediatr Nephrol; 2006 Jun; 21(6):807-10. PubMed ID: 16703374
[TBL] [Abstract][Full Text] [Related]
14. In vitro screening of probiotic properties of Saccharomyces cerevisiae var. boulardii and food-borne Saccharomyces cerevisiae strains.
van der Aa Kühle A; Skovgaard K; Jespersen L
Int J Food Microbiol; 2005 May; 101(1):29-39. PubMed ID: 15878404
[TBL] [Abstract][Full Text] [Related]
15. Strain engineering and metabolic flux analysis of a probiotic yeast Saccharomyces boulardii for metabolizing L-fucose, a mammalian mucin component.
Kim J; Cheong YE; Yu S; Jin YS; Kim KH
Microb Cell Fact; 2022 Oct; 21(1):204. PubMed ID: 36207743
[TBL] [Abstract][Full Text] [Related]
16. Identification and Growth Characterization of a Novel Strain of
Hossain MN; Afrin S; Humayun S; Ahmed MM; Saha BK
Front Nutr; 2020; 7():27. PubMed ID: 32309286
[TBL] [Abstract][Full Text] [Related]
17. Review article: anti-inflammatory mechanisms of action of Saccharomyces boulardii.
Pothoulakis C
Aliment Pharmacol Ther; 2009 Oct; 30(8):826-33. PubMed ID: 19706150
[TBL] [Abstract][Full Text] [Related]
18. Microbiome Engineering Using Probiotic Yeast:
Kim J; Atkinson C; Miller MJ; Kim KH; Jin YS
Microbiol Spectr; 2023 Aug; 11(4):e0078023. PubMed ID: 37436157
[TBL] [Abstract][Full Text] [Related]
19. Saccharomyces boulardii CNCM I-745: A Non-bacterial Microorganism Used as Probiotic Agent in Supporting Treatment of Selected Diseases.
Kaźmierczak-Siedlecka K; Ruszkowski J; Fic M; Folwarski M; Makarewicz W
Curr Microbiol; 2020 Sep; 77(9):1987-1996. PubMed ID: 32472262
[TBL] [Abstract][Full Text] [Related]
20. Functional heterologous protein expression by genetically engineered probiotic yeast Saccharomyces boulardii.
Hudson LE; Fasken MB; McDermott CD; McBride SM; Kuiper EG; Guiliano DB; Corbett AH; Lamb TJ
PLoS One; 2014; 9(11):e112660. PubMed ID: 25391025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
